Past Webinar
Unlock Early Access to Next-Generation Intravascular Imaging
We hosted an information session on the Early Access Program. Our team, along with our Chief Medical Officer Dr. Luis Savastano, provided a comprehensive overview of our breakthrough technology and discussed the benefits for early adopters.
02
By The Numbers*
50+
Our technology is backed by over 50 patents, protecting and advancing exclusive imaging and endoscopic capabilities.
Patents For Advancing Imaging and Endoscopic Capabilities
10x
Our single-use design is crafted with the goal of reducing cross-contamination risks by up to 10 times the current rate, supporting safer procedures for patients.
We Aim To Reduce Cross-Contamination Risks
30%
Our technology is developed to help streamline complex procedures, with the potential to reduce operating time and improve patient throughput.
Possible Reduction In Procedure Time With Improved Efficiency
1
Our endoscope is designed to contribute to cost efficiency, with the possibility of just one additional procedure offering measurable ROI.
Procedure Aims To Cover The Entire Unit Investment
99.99%
Our device aims to achieve illumination efficiency far beyond standard CMOS cameras, working to provide clear and precise imaging for diagnostics.
Illumination Efficiency Potential vs. Traditonal CMOS Solutions
40%
Our advanced imaging technology aspires to support higher success rates with the goal of improving patient outcomes.
Aiming For Higher Success Rates In Complex Cases
* Source: JACC: Cardiovascular Interventions. "Chronic Total Occlusion Percutaneous Coronary Interventions: Evidence, Techniques, and Outcomes." Accessed at https://www.jacc.org/doi/full/10.1016/j.jcin.2009.02.008.
SPEAKER:
Dr. Luis Savastano
DATE:
August 18, 2025
TIME:
9:00 AM (PDT - USA) | 12:00 PM (EDT - USA) | 6:00 PM (CET - Europe)
LOCATION:
Online
VerAvanti hosted an exclusive information session on the Early Access Program. Our team, along with guest speaker Dr. Luis Savastano, provided a comprehensive overview of our breakthrough technology and discussed the benefits for early adopters.
About the Speaker
Dr. Luis Savastano is a surgeon-scientist, inventor, and serial founder dedicated to solving unmet clinical needs through translational research and the development of breakthrough medical technologies. He currently serves at the University of California, San Francisco (UCSF) as Co-Chief of NeuroEndovascular Surgery, Medical Director of Cerebrovascular Neurosurgery, Program Director of the CAST-approved Cerebrovascular Fellowship, and Principal Investigator of the Translational Neurosurgery and Technology Lab (TNTLab).
As Chief Medical Officer at VerAvanti, Dr. Savastano plays a key role in shaping the company’s clinical research and validation strategy. He has conducted pioneering research on VerAvanti’s SFE platform and was among the earliest to explore its use in the evaluation of carotid artery disease and stroke, demonstrating its potential to provide real-time, high-resolution intravascular visualization. His work underscores a strong commitment to translating innovation into meaningful clinical tools that improve outcomes and reshape standards of care.
Webinar Highlights
This webinar covered key topics, including:
An in-depth look at the Early Access Program and its structure.
How VerAvanti's technology enhances imaging clarity and clinical workflow.
The operational and patient care benefits of early adoption.
The eligibility criteria and participation process for the program.
About VerAvanti
VerAvanti is dedicated to improving patient outcomes through our advanced SFE (Scanning Fiber Endoscope) technology. Our device will provide high-resolution imaging to address sightline gaps and enhance procedural accuracy in cardiology, neurosurgery, and peripheral artery interventions. The Early Access Program offers clinicians the opportunity to experience these benefits firsthand prior to full commercial launch.
🔗 Learn more about the Early Access Program: https://www.veravanti.com/earlyaccess